BCL2 and prostate carcinoma: Interestingly, BCL-2 inhibition, with venetoclax or siRNA, sensitizes taxane-resistant prostate cancer cells (PC3 and DU145) to cisplatin chemotherapy, with BCL-2 overexpression reversing this effect [207].